AKT1 and Miyoshi myopathy: Our study is also on similar lines as recent studies that have shown GRP78 as a therapeutic target in MM [39, 47, 48] and presents clear evidence that GRP78 activates PI3K/Akt signaling in MM, a pathway important for MM cell survival and resistance to existing therapies.